Ionis Pharmaceuticals reports FDA approval of Tryngolza

Ionis Pharmaceuticals (IONS) announced that the U.S. Food and Drug Administration (FDA) has approved Tryngolza as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome, a rare, genetic form of severe hypertriglyceridemia that can lead to potentially life-threatening acute pancreatitis. “Tryngolza is the first-ever FDA-approved treatment that significantly and substantially reduces triglyceride levels in adults with FCS and provides clinically meaningful reduction in AP events when used with an appropriate diet,” the company stated. Tryngolza is self-administered via an auto-injector once monthly. Tryngolza will be available in the U.S. before year end, the company stated.